Abstract PR8: Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer.

@inproceedings{Klein2013AbstractPN,
  title={Abstract PR8: Novel tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for immunotherapy of cancer.},
  author={Christian Klein and Waldhauer Inja and Valeria G. Nicolini and Dunn Claire and Anne Freimoser and Sylvia Herter and Edwin J. W. Geven and Otto C Boerman and Erwin van Puijenbroek and David Wittig and Samuel Moser and Oliver Ast and Ralf J. Hosse and Sabine Lang and Sebastian Neumann and Adelbert Grossmann and Ingo H. Gorr and Stefan Evers and Pavel Pi{\vs}a and Jennifer L Fretland and Victor Levitsky and Christian Gerdes and Marina Bacac and Ekkehard Moessner and Pablo Uma{\~n}a},
  year={2013}
}
Introduction: IL-2 therapy can lead to durable responses in a modest proportion of cancer patients, but the treatment is associated with significant toxicity. Over the last decades, various IL-2-based immunocytokines have been generated by fusing IL-2 to tumor-targeting antibodies. However, none of these molecules have progressed beyond Phase II trials and they are hampered by various liabilities: 1) High functional affinity (low pM) for IL-2Rabg on immune cells and on pulmonary vascular… CONTINUE READING